牛牛AI助理已提取核心訊息
Eli Lilly and Co (LLY.US), a global pharmaceutical company, reported a 20% increase in revenue to $34.1 billion for the year ended December 31, 2023, compared to $28.5 billion in 2022. However, net income decreased by 16% to $5.2 billion, and diluted earnings per share also fell by 16% to $5.80. The revenue growth was attributed to higher sales volumes and prices, particularly for products like Mounjaro, Verzenio, and Jardiance, as well as income from the sale of rights for the olanzapine portfolio. The decline in net income and earnings per share was primarily due to higher research and development expenses and increased marketing, selling, and administrative expenses. Eli Lilly's late-stage pipeline includes approximately 50 new medicine candidates, with several in Phase II or III clinical trials or...Show More
Eli Lilly and Co (LLY.US), a global pharmaceutical company, reported a 20% increase in revenue to $34.1 billion for the year ended December 31, 2023, compared to $28.5 billion in 2022. However, net income decreased by 16% to $5.2 billion, and diluted earnings per share also fell by 16% to $5.80. The revenue growth was attributed to higher sales volumes and prices, particularly for products like Mounjaro, Verzenio, and Jardiance, as well as income from the sale of rights for the olanzapine portfolio. The decline in net income and earnings per share was primarily due to higher research and development expenses and increased marketing, selling, and administrative expenses. Eli Lilly's late-stage pipeline includes approximately 50 new medicine candidates, with several in Phase II or III clinical trials or under regulatory review. The company's future plans focus on continuing to develop and commercialize innovative medicines, with significant investments in research and development, as well as manufacturing capacity expansion to meet the demand for its incretin products. Eli Lilly also anticipates challenges in supply and demand management for these products. The company's financial condition remains strong, with sufficient cash and cash equivalents to fund its capital requirements, including working capital, capital expenditures, share repurchases, and dividends.
全球製藥公司禮來公司（LLY.US）報告稱，截至2023年12月31日的財年，收入增長了20％，達到341億美元，而2022年爲285億美元。但是，淨收入下降了16％，至52億美元，攤薄後的每股收益也下降了16％，至5.80美元。收入增長歸因於銷量和價格的增加，尤其是Mounjaro、Verzenio和Jardiance等產品的銷量和價格的增加，以及出售奧氮平投資組合版權的收入。淨收益和每股收益的下降主要是由於研發費用增加以及營銷、銷售和管理費用的增加。禮來公司的後期產品線包括約50種新的候選藥物，其中幾種處於二期或三期臨床試驗或監管審查中。該公司的未來計劃側重於繼續開發和商業化創新藥物，在研發方面進行大量投資，並擴大產能以滿足對其incretin產品的需求。禮來公司還預計，這些產品的供需管理將面臨挑戰。該公司的財務狀況仍然強勁，有足夠的現金和現金等價物爲其資本需求提供資金，包括營運資金、資本支出、股票回購和股息。
全球製藥公司禮來公司（LLY.US）報告稱，截至2023年12月31日的財年，收入增長了20％，達到341億美元，而2022年爲285億美元。但是，淨收入下降了16％，至52億美元，攤薄後的每股收益也下降了16％，至5.80美元。收入增長歸因於銷量和價格的增加，尤其是Mounjaro、Verzenio和Jardiance等產品的銷量和價格的增加，以及出售奧氮平投資組合版權的收入。淨收益和每股收益的下降主要是由於研發費用增加以及營銷、銷售和管理費用的增加。禮來公司的後期產品線包括約50種新的候選藥物，其中幾種處於二期或三期臨床試驗或監管審查中。該公司的未來計劃側重於繼續開發和商業化創新藥物，在研發方面進行大量投資，並擴大產能以滿足對其incretin產品的需求。禮來公司還預計，這些產品的供需管理將面臨挑戰。該公司的財務狀況仍然強勁，有足夠的現金和現金等價物爲其資本需求提供資金，包括營運資金、資本支出、股票回購和股息。
有用
沒用